+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Lumigan"

From
The Global Ophthalmic Drugs Market - Product Thumbnail Image

The Global Ophthalmic Drugs Market

  • Report
  • October 2018
  • 104 Pages
  • Global
From
Lumigan RC - API Insight, 2022 - Product Thumbnail Image

Lumigan RC - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
Lumigan RC- Drug Insight, 2019 - Product Thumbnail Image

Lumigan RC- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
  • 5 Results (Page 1 of 1)
Loading Indicator

Lumigan is a brand name for the drug bimatoprost, an ophthalmic solution used to treat glaucoma and other eye disorders. It is a prostaglandin analog, which works by decreasing the pressure in the eye by increasing the outflow of fluid from the eye. Lumigan is available in both a 0.03% and 0.01% concentration, and is typically administered once daily in the evening. It is available in both a single-use bottle and a multi-use bottle. Lumigan is a popular treatment for glaucoma and other eye disorders, and is widely prescribed by ophthalmologists. It is also used off-label to treat alopecia, a condition characterized by hair loss. Lumigan is generally well-tolerated, with the most common side effects being eye irritation, redness, and dryness. The Lumigan market is highly competitive, with a number of companies offering similar products. Some of the major players in the market include Allergan, Pfizer, Novartis, Merck, and Bausch & Lomb. Show Less Read more